Antimicrobial Resistance Diagnostics Market Size, Share | Report 2022-2030
The global antimicrobial resistance diagnostics market was surpassed at USD 3.5 billion in 2021 and is expected to hit around USD 7.3 billion by 2030, growing at a CAGR of 8.51% from 2022 to 2030.
The growth of the antimicrobial resistance diagnostics market is attributed to the increased risk of developing drug-resistant bacterial infections, the introduction of novel technologies, and increasing government initiatives to diagnose & reduce AMR infections. To address the global health challenge of AMR, government bodies such as the U.S. FDA support the development of next-generation sequencing-based diagnostic tests to identify the right pathogen to help healthcare providers to treat infections more accurately.
Increasing adoption of point of care and rapid testing for drug-resistant microbial infections is expected to fuel the market growth in the forecast period. PCR technology-based POC tests are expected to control the progression of hospital-acquired infections (HAIs) in healthcare facilities. Moreover, key market players such as Abbott, F. Hoffmann-La Roche Ltd, and others have a strong product portfolio of rapid diagnostic tests for multiple drug-resistant infections. Moreover, increasing involvement of government and non-government bodies such as the AMR Industry Alliance is helping to build strategies to support diagnostic development to reduce antimicrobial resistance.
The AMR diagnostics market is segmented based on technology, pathogen, and end-user. Among the technology segment, the polymerase chain reaction segment held the largest share in 2021 and is expected to maintain its dominance through the forecast period. High penetration of PCR technology and advancements in the technology has increased the segment share. Moreover, the high adoption rate of PCR tests for HAIs such as c. difficile and MRSA is further driving segment growth. However, the rapid & point of care segment is anticipated to grow at the fastest rate in the forecast period.
North America is the largest market for antimicrobial resistance diagnostics. The high risk of developing AMR infections, developed healthcare infrastructure, favorable healthcare policies, and presence of key market players in the region have increased the market share. According to an article published by CDC in August 2022, in the U.S., around 2.8 million people are diagnosed with antibiotic-resistant infections each year. MRSA and c.difficile are major prevalent infections reported in the U.S. However, the Asia Pacific is expected to grow at the fastest rate during the forecast period. The growth of the region can be attributed to the increasing adoption of novel diagnostic techniques, improving healthcare policies, and increasing awareness among people is expected to fuel the segment growth in the region.
Scope of The Report
| Report Coverage | Details |
| Market Size in 2021 | USD 3.5 billion |
| Revenue Forecast by 2030 | USD 7.3 billion |
| Growth rate from 2022 to 2030 | CAGR of 8.51% |
| Base Year | 2021 |
| Forecast Period | 2022 to 2030 |
| Segmentation | Technology, Pathogen, End-User, Region |
| Companies Covered |
F. Hoffmann-La Roche, Ltd., Abbott, BD, Danaher, and Accelerate Diagnostics, Inc. |
Key Players
Market Segmentation
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Antimicrobial Resistance Diagnostics Market
5.1. COVID-19 Landscape: Antimicrobial Resistance Diagnostics Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Antimicrobial Resistance Diagnostics Market, By Technology
8.1. Antimicrobial Resistance Diagnostics Market, by Technology, 2022-2030
8.1.1 Microbiology Culture
8.1.1.1. Market Revenue and Forecast (2017-2030)
8.1.2. Immunoassay
8.1.2.1. Market Revenue and Forecast (2017-2030)
8.1.3. PCR
8.1.3.1. Market Revenue and Forecast (2017-2030)
8.1.4. NGS
8.1.4.1. Market Revenue and Forecast (2017-2030)
8.1.5. Mass Spectrometry
8.1.5.1. Market Revenue and Forecast (2017-2030)
8.1.6. Rapid & Point of Care
8.1.6.1. Market Revenue and Forecast (2017-2030)
8.1.7. Others
8.1.7.1. Market Revenue and Forecast (2017-2030)
Chapter 9. Global Antimicrobial Resistance Diagnostics Market, By Pathogen
9.1. Antimicrobial Resistance Diagnostics Market, by Pathogen, 2022-2030
9.1.1. Drug Resistant Streptococcus Pneumoniae (DRSP)
9.1.1.1. Market Revenue and Forecast (2017-2030)
9.1.2. Drug Resistant Campylobacter (DRC)
9.1.2.1. Market Revenue and Forecast (2017-2030)
9.1.3. Clostridium Difficile (CD)
9.1.3.1. Market Revenue and Forecast (2017-2030)
9.1.4. Methicillin Resistant Staphylococcus Aureus (MRSA)
9.1.4.1. Market Revenue and Forecast (2017-2030)
9.1.5. Drug Resistant Neisseria Gonorrhoeae (DRNG)
9.1.5.1. Market Revenue and Forecast (2017-2030)
9.1.6. Drug Resistant Salmonella (DRNTS)
9.1.6.1. Market Revenue and Forecast (2017-2030)
9.1.7. Others
9.1.7.1. Market Revenue and Forecast (2017-2030)
Chapter 10. Global Antimicrobial Resistance Diagnostics Market, By End-User
10.1. Antimicrobial Resistance Diagnostics Market, by End-User, 2022-2030
10.1.1. Hospitals
10.1.1.1. Market Revenue and Forecast (2017-2030)
10.1.2. Diagnostic Laboratories
10.1.2.1. Market Revenue and Forecast (2017-2030)
10.1.3. Pharmaceutical & Biotechnology Companies
10.1.3.1. Market Revenue and Forecast (2017-2030)
10.1.4. Others
10.1.4.1. Market Revenue and Forecast (2017-2030)
Chapter 11. Global Antimicrobial Resistance Diagnostics Market, Regional Estimates and Trend Forecast
11.1. North America
11.1.1. Market Revenue and Forecast, by Technology (2017-2030)
11.1.2. Market Revenue and Forecast, by Pathogen (2017-2030)
11.1.3. Market Revenue and Forecast, by End-User (2017-2030)
11.1.4. U.S.
11.1.4.1. Market Revenue and Forecast, by Technology (2017-2030)
11.1.4.2. Market Revenue and Forecast, by Pathogen (2017-2030)
11.1.4.3. Market Revenue and Forecast, by End-User (2017-2030)
11.1.5. Rest of North America
11.1.5.1. Market Revenue and Forecast, by Technology (2017-2030)
11.1.5.2. Market Revenue and Forecast, by Pathogen (2017-2030)
11.1.5.3. Market Revenue and Forecast, by End-User (2017-2030)
11.2. Europe
11.2.1. Market Revenue and Forecast, by Technology (2017-2030)
11.2.2. Market Revenue and Forecast, by Pathogen (2017-2030)
11.2.3. Market Revenue and Forecast, by End-User (2017-2030)
11.2.4. UK
11.2.4.1. Market Revenue and Forecast, by Technology (2017-2030)
11.2.4.2. Market Revenue and Forecast, by Pathogen (2017-2030)
11.2.4.3. Market Revenue and Forecast, by End-User (2017-2030)
11.2.5. Germany
11.2.5.1. Market Revenue and Forecast, by Technology (2017-2030)
11.2.5.2. Market Revenue and Forecast, by Pathogen (2017-2030)
11.2.5.3. Market Revenue and Forecast, by End-User (2017-2030)
11.2.6. France
11.2.6.1. Market Revenue and Forecast, by Technology (2017-2030)
11.2.6.2. Market Revenue and Forecast, by Pathogen (2017-2030)
11.2.6.3. Market Revenue and Forecast, by End-User (2017-2030)
11.2.7. Rest of Europe
11.2.7.1. Market Revenue and Forecast, by Technology (2017-2030)
11.2.7.2. Market Revenue and Forecast, by Pathogen (2017-2030)
11.2.7.3. Market Revenue and Forecast, by End-User (2017-2030)
11.3. APAC
11.3.1. Market Revenue and Forecast, by Technology (2017-2030)
11.3.2. Market Revenue and Forecast, by Pathogen (2017-2030)
11.3.3. Market Revenue and Forecast, by End-User (2017-2030)
11.3.4. India
11.3.4.1. Market Revenue and Forecast, by Technology (2017-2030)
11.3.4.2. Market Revenue and Forecast, by Pathogen (2017-2030)
11.3.4.3. Market Revenue and Forecast, by End-User (2017-2030)
11.3.5. China
11.3.5.1. Market Revenue and Forecast, by Technology (2017-2030)
11.3.5.2. Market Revenue and Forecast, by Pathogen (2017-2030)
11.3.5.3. Market Revenue and Forecast, by End-User (2017-2030)
11.3.6. Japan
11.3.6.1. Market Revenue and Forecast, by Technology (2017-2030)
11.3.6.2. Market Revenue and Forecast, by Pathogen (2017-2030)
11.3.6.3. Market Revenue and Forecast, by End-User (2017-2030)
11.3.7. Rest of APAC
11.3.7.1. Market Revenue and Forecast, by Technology (2017-2030)
11.3.7.2. Market Revenue and Forecast, by Pathogen (2017-2030)
11.3.7.3. Market Revenue and Forecast, by End-User (2017-2030)
11.4. MEA
11.4.1. Market Revenue and Forecast, by Technology (2017-2030)
11.4.2. Market Revenue and Forecast, by Pathogen (2017-2030)
11.4.3. Market Revenue and Forecast, by End-User (2017-2030)
11.4.4. GCC
11.4.4.1. Market Revenue and Forecast, by Technology (2017-2030)
11.4.4.2. Market Revenue and Forecast, by Pathogen (2017-2030)
11.4.4.3. Market Revenue and Forecast, by End-User (2017-2030)
11.4.5. North Africa
11.4.5.1. Market Revenue and Forecast, by Technology (2017-2030)
11.4.5.2. Market Revenue and Forecast, by Pathogen (2017-2030)
11.4.5.3. Market Revenue and Forecast, by End-User (2017-2030)
11.4.6. South Africa
11.4.6.1. Market Revenue and Forecast, by Technology (2017-2030)
11.4.6.2. Market Revenue and Forecast, by Pathogen (2017-2030)
11.4.6.3. Market Revenue and Forecast, by End-User (2017-2030)
11.4.7. Rest of MEA
11.4.7.1. Market Revenue and Forecast, by Technology (2017-2030)
11.4.7.2. Market Revenue and Forecast, by Pathogen (2017-2030)
11.4.7.3. Market Revenue and Forecast, by End-User (2017-2030)
11.5. Latin America
11.5.1. Market Revenue and Forecast, by Technology (2017-2030)
11.5.2. Market Revenue and Forecast, by Pathogen (2017-2030)
11.5.3. Market Revenue and Forecast, by End-User (2017-2030)
11.5.4. Brazil
11.5.4.1. Market Revenue and Forecast, by Technology (2017-2030)
11.5.4.2. Market Revenue and Forecast, by Pathogen (2017-2030)
11.5.4.3. Market Revenue and Forecast, by End-User (2017-2030)
11.5.5. Rest of LATAM
11.5.5.1. Market Revenue and Forecast, by Technology (2017-2030)
11.5.5.2. Market Revenue and Forecast, by Pathogen (2017-2030)
11.5.5.3. Market Revenue and Forecast, by End-User (2017-2030)
Chapter 12. Company Profiles
12.1. F. Hoffmann-La Roche, Ltd.
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. Abbott
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. BD
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. Danaher
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. Accelerate Diagnostics, Inc.
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
Chapter 13. Research Methodology
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
Chapter 14. Appendix
14.1. About Us
14.2. Glossary of Terms
Cross-segment Market Size and Analysis for
Mentioned Segments
Additional Company Profiles (Upto 5 With No Cost)
Additional Countries (Apart From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers